Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

778 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
Nagahara A, Uemura M, Sato M, Nakata W, Tsujihata M, Takao T, Matsumura S, Nishimura K, Takada S, Iwanishi T, Kobayashi Y, Ishizuya Y, Takada T, Okada K, Inoue H, Kato T, Hatano K, Kawashima A, Ujike T, Fujita K, Nonomura N. Nagahara A, et al. Among authors: takao t. Jpn J Clin Oncol. 2024 May 7;54(5):584-591. doi: 10.1093/jjco/hyae004. Jpn J Clin Oncol. 2024. PMID: 38305451 Free PMC article.
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
Kato T, Fujita K, Minami T, Nagahara A, Hyashi Y, Nakata W, Matsuzaki K, Nakano K, Hatano K, Kawashima A, Imamura R, Takada S, Nishimura K, Tsujihata M, Takao T, Nakai Y, Nakayama M, Nishimura K, Uemura M, Uemura H, Nonomura N. Kato T, et al. Among authors: takao t. Int J Clin Oncol. 2022 Oct;27(10):1596-1604. doi: 10.1007/s10147-022-02215-8. Epub 2022 Jul 13. Int J Clin Oncol. 2022. PMID: 35831538
The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study.
Kato T, Nagahara A, Kawamura N, Nakata W, Soda T, Matsuzaki K, Hatano K, Kawashima A, Ujike T, Imamura R, Nishimura K, Takada S, Tsujihata M, Yamaguchi S, Takao T, Nishimura K, Nonomura N, Uemura M. Kato T, et al. Among authors: takao t. Int J Clin Oncol. 2021 May;26(5):954-961. doi: 10.1007/s10147-021-01872-5. Epub 2021 Jan 20. Int J Clin Oncol. 2021. PMID: 33471290
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Kato T, Nagahara A, Kawamura N, Nakata W, Soda T, Matsuzaki K, Hatano K, Kawashima A, Ujike T, Imamura R, Nishimura K, Takada S, Tsujihata M, Yamaguchi S, Takao T, Nakai Y, Nakayama M, Nonomura N, Uemura M. Kato T, et al. Among authors: takao t. Anticancer Res. 2021 Nov;41(11):5811-5816. doi: 10.21873/anticanres.15398. Anticancer Res. 2021. PMID: 34732455
A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan.
Kato T, Yumiba S, Nakata W, Nakano K, Nagahara A, Matsuzaki K, Hayashi Y, Hatano K, Kawashima A, Takao T, Nishimura K, Nakai Y, Nakayama M, Nishimura K, Takada S, Tsujihata M, Uemura M, Nonomura N, Imamura R. Kato T, et al. Among authors: takao t. Int J Urol. 2023 Sep;30(9):723-729. doi: 10.1111/iju.15130. Epub 2022 Dec 28. Int J Urol. 2023. PMID: 36578154
778 results